The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.

被引：1
作者：
Mustacchi, Giorgio
Cazzaniga, Marina Elena
Romagnoli, Emanuela
Montemurro, Filippo
De laurentiis, Michele
Riccardi, Ferdinando
Turletti, Anna
Beano, Alessandra
De Angelis, Claudia
Graziano, Vincenzo
Livi, Lorenzo
Del Mastro, Lucia
Biganzoli, Laura
Garrone, Ornella
De Placido, Sabina
Marchetti, Paolo
Pronzato, Paolo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：6
相关论文
共 50 条
[41]   Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13-AMBRA Study [J].
Cazzaniga, Marina Elena ;
Pronzato, Paolo ;
Amoroso, Domenico ;
Arpino, Grazia ;
Atzori, Francesco ;
Beano, Alessandra ;
Biganzoli, Laura ;
Bisagni, Giancarlo ;
Blasi, Livio ;
Capello, Cristina ;
Chiari, Rita ;
D'Alonzo, Alessia ;
De Laurentiis, Michelino ;
Denaro, Angela ;
Fabi, Alessandra ;
Farci, Daniele ;
Ferrau, Francesco ;
Fiorio, Elena ;
Gennari, Alessandra ;
Giotta, Francesco ;
Giovanardi, Filippo ;
Gregorc, Vanesa ;
Livi, Lorenzo ;
Magnolfi, Emanuela ;
Mosconi, Anna Maria ;
Palumbo, Raffaella ;
Pugliese, Palma ;
Putzu, Carlo ;
Ricciardi, Giuseppina Rosaria Rita ;
Riccardi, Ferdinando ;
Scortichini, Laura ;
Spazzapan, Simon ;
Tagliaferri, Pierosandro ;
Tinari, Nicola ;
Tonini, Giuseppe ;
Vandone, Anna Maria ;
Mustacchi, Giorgio .
CANCERS, 2025, 17 (10)
[42]   Results of a retrospective study on the efficacy and safety of alpelisib in patients with HR+/HER2-metastatic breast cancer in real-world clinical practice [J].
Sultanbaev, Alexander Valerievich ;
Kolyadina, Irina Vladimirovna ;
Menshikov, Konstantin ;
Musin, Shamil ;
Sultanbaeva, Nadezda ;
Lipatov, Danila .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43]   Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from the Mexican Oncology Study Group. [J].
Torrecillas, L ;
Soto, C ;
Cervantes, G ;
Benitez, H ;
Acosta, A ;
Cortes, P ;
Gonzalez, F ;
Zamora, R ;
Rodriguez, G ;
Silva, A ;
Leoner, C ;
Sauza, F ;
Suarez, T ;
Tokunaga, J ;
Erazo, A ;
Talavera, J .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 :S200-S200
[44]   Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study [J].
Lopez Gonzalez, A. ;
Del Barco Berron, S. ;
Garau Llinas, I. ;
Galan Gramaje, M. ;
Castelo, B. ;
Cortes Salgado, A. ;
Sanchez-Rovira, P. ;
Martinez Bueno, A. ;
Garcia, A. ;
Gener, P. ;
Mina, L. ;
Alcala, D. ;
Sampayo-Cordero, M. ;
Cortes, J. ;
Perez Garcia, J. M. ;
Llombart Cussac, A. ;
Lopez Miranda, E. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S661-S662
[45]   Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. [J].
Alva, Ajjai Shivaram ;
Mangat, Pam K. ;
Garrett-Mayer, Elizabeth ;
Halabi, Susan ;
Alvarez, Ricardo H. ;
Calfa, Carmen Julia ;
Khalil, Maged F. ;
Ahn, Eugene R. ;
Cannon, Timothy Lewis ;
Crilley, Pamela A. ;
Fisher, Julie Gottlieb ;
Haslem, Derrick S. ;
Shrestha, Sagun ;
Antonelli, Kaitlyn R. ;
Butler, Nicole L. ;
Warren, Sasha L. ;
Rygiel, Andrew Lawrence ;
Ranasinghe, Shamika ;
Bruinooge, Suanna S. ;
Schilsky, Richard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[46]   Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. [J].
Calfa, Carmen ;
Rothe, Michael ;
Mangat, Pam K. ;
Garrett-Mayer, Elizabeth ;
Ahn, Eugene ;
Gogineni, Keerthi ;
Rohatgi, Nitin ;
Burness, Monika L. ;
Gaba, Anu ;
Hamid, Omid ;
Albaghdadi, Tareq ;
Conlin, Alison ;
Gold, Philip ;
Rodon, Jordi ;
Thota, Ramya ;
Schilsky, Richard L. .
CANCER RESEARCH, 2021, 81 (13)
[47]   Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2-Positive Metastatic Breast Cancer from the registHER Observational Study. [J].
Kaufman, P. A. ;
Brufsky, A. M. ;
Mayer, M. ;
Rugo, H. S. ;
Tripathy, D. ;
Ulcickas, Yood M. ;
Feng, S. ;
Wang, L. I. ;
Brammer, M. G. ;
Yardley, D. A. .
CANCER RESEARCH, 2011, 71
[48]   Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcomes in 4145 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)-Results from the French ESME UNICANCER program [J].
Le Du, Fanny ;
Carton, Matthieu ;
Saghatchian, Mahasti ;
Perol, David ;
Pistilli, Barbara ;
Brain, Etienne ;
Loirat, Delphine ;
Vanlemmens, Laurence ;
Vermeulin, Thomas ;
Levy, Christelle ;
Goncalves, Anthony ;
Ung, Mony ;
Robert, Marie ;
Jaffre, Anne ;
Robain, Mathieu ;
Delaloge, Suzette ;
Dieras, Veronique .
CANCER RESEARCH, 2022, 82 (04)
[49]   Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcome in 2863 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)-Results from the French ESME UNICANCER program [J].
Saghatchian, Mahasti ;
Carton, Matthieu ;
Piot, Irwin ;
Perol, David ;
Pistilli, Barbara ;
Brain, Etienne ;
Ghouadni, Amal ;
Ricci, Francesco ;
Vanlemmens, Laurence ;
Loeb, Agnes ;
Levy, Christelle ;
Goncalves, Anthony ;
Dalenc, Florence ;
Lefeuvre-Plesse, Claudia ;
Campone, Mario ;
Jaffre, Anne ;
Gourgou, Sophie ;
Cailliot, Christian ;
Robain, Mathieu ;
Dieras, Veronique .
CANCER RESEARCH, 2018, 78 (04)
[50]   Everolimus in combination with weekly paciltaxel and transtuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trail. [J].
Dalenc, F. ;
Campone, M. ;
Hupperets, P. ;
O'Regan, R. ;
Manlius, C. ;
Vittori, L. ;
Mukhopadhyay, P. ;
Massacesi, C. ;
Sahmoud, T. ;
Andre, F. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345